Berlex' Ultravist x-ray/CT imaging agent approved May 10; launch slated for July.
This article was originally published in The Gray Sheet
BERLEX ULTRAVIST CONTRAST AGENT WILL BE AVAILABLE IN JULY, the company announced May 12. The iodinated, non-ionic contrast agent iopromide for x-ray imaging and computed tomography scanning was approved by FDA on May 10, almost two years after FDA's Medical Imaging Drugs Advisory Committee unanimously recommended approval for eight indications ("The Gray Sheet" May 31, 1993, p. 14).
You may also be interested in...
Business development leaders and venture capital investors spoke at Biocom’s annual partnering conference about what they are seeking in relationships with entrepreneurs and start-ups.
Mylan’s full year 2019 earnings report was its last as an independent company, so the focus was on the coming merger with Pfizer’s Upjohn and growth prospects for the new company, Viatris.
Colgate Zero toothpastes and mouthwashes promote what’s missing; Tom’s of Maine natural personal care expands with prebiotic toothpaste, deodorant and hand soap; Gaia adds hemp to its herbs; and Church & Dwight goes environmentally friendly with VitaFusion Goodness supplements, adds CBD versions to line, too.